INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
INmune Bio secured MHRA approval for the Pediatric Investigation Plan for Ebstrocel, validating its clinical data package for RDEB treatment. The accelerated review, completed in under three months, keeps the company on track for a UK Marketing Authorization Application in 2026 and a US filing in early 2027.
Key figures
- Uk eb total population
- 5000
- Uk rdeb pediatric population
- 300
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.